Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Martina Sintzel"'
Autor:
Wallace J Brownlee, Christian Wolf, Hans-Peter Hartung, Theo Dingermann, Nadia Anshasi, Richard AC Clark, Maria Trojano, Krzysztof Selmaj, Bernard MJ Uitdehaag, Carmen Tur, Jens Wuerfel, Gabriele Dallmann, Julian Witte, Martina Sintzel, Olga Bobrovnikova, Jeffrey A Cohen
Publikováno v:
Multiple Sclerosis Journal, 28(14), 2177-2189. SAGE Publications Ltd
Brownlee, W J, Wolf, C, Hartung, H-P, Dingermann, T, Anshasi, N, Clark, R A C, Trojano, M, Selmaj, K, Uitdehaag, B M J, Tur, C, Wuerfel, J, Dallmann, G, Witte, J, Sintzel, M, Bobrovnikova, O & Cohen, J A 2022, ' Use of follow-on disease-modifying treatments for multiple sclerosis : Consensus recommendations ', Multiple Sclerosis Journal, vol. 28, no. 14, pp. 2177-2189 . https://doi.org/10.1177/13524585221116269
Brownlee, W J, Wolf, C, Hartung, H-P, Dingermann, T, Anshasi, N, Clark, R A C, Trojano, M, Selmaj, K, Uitdehaag, B M J, Tur, C, Wuerfel, J, Dallmann, G, Witte, J, Sintzel, M, Bobrovnikova, O & Cohen, J A 2022, ' Use of follow-on disease-modifying treatments for multiple sclerosis : Consensus recommendations ', Multiple Sclerosis Journal, vol. 28, no. 14, pp. 2177-2189 . https://doi.org/10.1177/13524585221116269
Background: As patents for multiple sclerosis (MS) therapies expire, follow-on disease-modifying treatments (FO-DMTs) become available at reduced cost. Concerns exist that cheaper FO-DMTs are used simply to reduce healthcare costs. However, the well-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76c5b38de7215defadd844af514b4860
https://doi.org/10.1177/13524585221116269
https://doi.org/10.1177/13524585221116269
Autor:
François Cotton, David Leppert, Charles R.G. Guttmann, Chiara Zecca, Dominik S. Meier, Claudio Gobbi, Martina Sintzel
Publikováno v:
BMC Neurology
BMC Neurology, BioMed Central, 2013, 13 (1), pp.101. ⟨10.1186/1471-2377-13-101⟩
BMC Neurology, 2013, 13 (1), pp.101. ⟨10.1186/1471-2377-13-101⟩
BMC Neurology, BioMed Central, 2013, 13 (1), pp.101. ⟨10.1186/1471-2377-13-101⟩
BMC Neurology, 2013, 13 (1), pp.101. ⟨10.1186/1471-2377-13-101⟩
Background Natalizumab (NTZ) discontinuation leads to multiple sclerosis reactivation. The objective of this study is to compare disease activity in MS patients who continued on NTZ treatment to those who were switched to subcutaneous interferon 1b (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1fe1e060ff976cf0888826e5899bb0b
https://www.hal.inserm.fr/inserm-00850833/file/1471-2377-13-101.pdf
https://www.hal.inserm.fr/inserm-00850833/file/1471-2377-13-101.pdf
